Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,809 total articles
Abercrombie & Fitch (ANF) is trading near $96 with strong cash flow, a lean balance sheet and an EV/EBITDA around 4.3. Fundamentals show high ROE (≈39.6%) and free cash flow of $384.5M, implying the stock is priced for modest growth. This trade idea argues for a long position sized prudently, with an entry at $96.00, stop at $85.00 and target at $1…
Berkshire Hathaway looks reasonably priced at roughly $487.50 with a P/E near 15.7, a modest P/B of ~1.5 and a near‑record cash war chest of $373.3B. Given the new leadership under Greg Abel and the company’s diversified earnings streams, a measured long position offers attractive asymmetry. Trade plan: enter at $487.50, target $540.00, stop $455.1…
Carnival (CCL) offers a pragmatic income trade: a modest current yield, below-market valuation (P/E ~14), and meaningful free cash flow ($2.6B) support a dividend-focused long trade. Technicals are soft but manageable; use a conservative stop and target near the 52-week high for a low-risk, income-oriented position over the next 180 trading days.
UroGen (URGN) recently re-rated as ZUSDURI builds clinical credibility for treating recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). With a market cap near $980M, durable efficacy data and an experienced commercialization push, ZUSDURI has the potential to replace TURBT in specific patient cohorts, supporting upsid…
USANA Health Sciences (USNA) trades at a valuation that looks disconnected from its balance-sheet strength and recent top-line momentum. With no debt, positive free cash flow ($18.7M last reported), an EV/EBITDA of ~3.0 and a market cap around $355M, USNA offers a low-leverage way to play recovery in the functional supplements market. This trade id…
Antero Midstream (AM) is trading near its 52-week highs on durable free cash flow, an accretive $1.1B HG Mid acquisition and management guidance for higher adjusted EBITDA and FCF in 2026. The combination of predictable midstream cash generation, balance-sheet improvement and active capital returns makes a tactical long attractive over a 180-tradin…
Cushman & Wakefield (CWK) is a leveraged but cash-generative commercial real estate services firm where valuation and free cash flow offer an asymmetric trade setup today. The recent lawsuit headline has injected volatility, but fundamentals - $293M in free cash flow, EV/EBITDA ~9, and EV/FCF in the mid-teens - argue for a long-biased, risk-defined…
IAMGOLD (IAG) reported record production in 2025, is guiding for further strong output in 2026, and sits on a relatively clean balance sheet. With gold above $4,700/oz and operational momentum, the stock looks attractive for a mid-term swing trade. Entry, target and stop are laid out below, along with catalysts, valuation framing and balanced risks…
Leidos (LDOS) is a market-cap ~ $22.3B defense and government-services platform trading at ~15.8x earnings with $1.63B free cash flow and a recently announced $2.4B acquisition that expands exposure to critical power infrastructure. We view the current pullback as a long-term (180 trading days) buying opportunity, but the trade rests on deal execut…
Walmart is a defensive giant with pricing power and operational scale, but a bumpy tariff backdrop and elevated valuation justify a measured, swing-oriented long. This trade targets a disciplined pullback entry, a reasonable upside to recent highs, and a stop that respects near-term volatility.
Equinor is trading near a 52-week high on positive headlines — buybacks and fresh Norwegian licenses — but momentum has room to run. Market-cap ~$81.98B, P/E ~16, and a 3.49% yield support a mid-term long. Trade plan provided for a mid-term (45 trading days) swing with defined risk controls.
Barclays (BCS) looks attractively priced after the market cooled off. The shares trade at about $23.36 with a market cap near $80.6B, a P/B around 0.91 and P/E roughly 10. With technical indicators showing oversold momentum and a wide 52-week range, this trade targets a re-rating toward the prior highs while keeping a tight stop to manage macro and…
Amylyx (AMLX) presents a high-risk, high-reward trade: the stock is trading at $15.05 with roughly $8.73 in cash per share and a $1.65B market cap. Positive LUCIDITY data expected by Q3 could materially re-rate shares; downside is meaningful if the readout disappoints or commercialization progress for other programs stalls. Our trade plan targets $…
Western Digital sits at the intersection of hyperscale storage demand and legacy HDD scale economics. With multi-year cloud contracts, improving margins and a market cap near $88.5B, WDC is a plausible play on continued AI data-center spending. This trade idea lays out an actionable long with a clear entry, stop and target, plus the catalysts and r…
StoneCo's shares trade at $14.29 with a sub-9x P/E and a $3.88B market cap after a volatile week. I am adding to my position because a modest repurchase program would translate into a double-digit buyback yield at today's valuation — and the company’s recent operating beats support that play.
Western Digital (WDC) looks like a compelling buy on the pullback caused by Sandisk-related share sales. Strong free cash flow, fat returns on equity, and multi-year data-center demand for high-capacity storage give WDC a credible path higher. I’m upgrading the trade rating to long with an entry at $263.50, stop at $210.00 and a target of $380.00 o…
Moderna cleared a major legal overhang with a $950M settlement and has an FDA PDUFA goal date of 08/05/2026 on its seasonal flu application. With a market cap near $23.4B, negative free cash flow narrowing, and strong technical momentum, we initiate a buy with a mid-term horizon and defined risk controls.
DexCom looks set to benefit from an underappreciated demand tailwind as CGMs (continuous glucose monitors) are being prescribed alongside GLP-1 therapies. The stock is trading around $73, offers solid free cash flow and high ROE, and technicals show constructive momentum. This trade lays out a precise entry, stop and target for a long position over…
Simmons First (SFNC) is showing the hallmarks of a genuine turnaround: strong free cash flow, a rising dividend and a valuation below tangible book. The bank remains unprofitable on the headline EPS line, but low leverage, an attractive yield and a compact market cap create an asymmetric risk-reward for long-term value hunters. This is an upgrade t…
RTX (RTX) is trading near multi-month highs as geopolitical risk and steady commercial programs drive demand. The company generates strong free cash flow and carries a defensible franchise across engines, avionics, sensors and missiles. We lay out an actionable long trade with entry, stop and target, plus catalysts and what would change our view.
Advanced Micro Devices is positioned to capture meaningful share and revenue upside from AI servers, PC Copilot+ chips, and large cloud deals. Valuation is rich versus history but justified by accelerating free cash flow, low leverage, and high-quality product momentum. We upgrade to a bullish trade with a clear entry, stop and target for a 180-tra…
Strathcona Resources (STHRF) trades at a low P/E and near-book valuation while showing bullish technicals and a 3.6% yield. We like a long position sized for conviction over a long-term trading horizon as the company scales thermal and EOR production and market sentiment normalizes.
International Seaways (INSW) sits near its 52-week high after a dramatic recovery from last year's lows. The company combines steady cash generation, a manageable debt load and an active capital-return policy. That mix supports a directional long with disciplined risk controls: enter near current levels, use a hard stop under the mid-$60s, and targ…
Expeditors (EXPD) looks like a classic cash-flow compounder that has been punished for a cyclical hit in ocean freight. With a market cap near $19.6B, roughly zero financial leverage, and $923M in free cash flow, the risk-reward supports a tactical long at current levels. This trade targets a recovery toward the 52-week high as AI and operational i…
Palantir is benefitting from renewed defense spending and a wave of commercial AIP adoption. Recent Q4 results, large government contracts, and elevated market attention create a window for a mid-term long trade. Valuation is rich, so risk-management and a clear stop are essential.
